The project

Due to the tight relationship between the liver and the gastrointestinal (GI) tract it is not surprising that intestinal dysbiosis has been associated with all stages of NAFLD, supported on evidences provided by manipulations of the microbiome in animal studies. Thus, it is crucial to leverage recent findings to research and develop novel diagnostic and therapeutic approaches involving gut microbiome, to tackle the growing societal problems caused by NAFLD (and possibly other chronic diseases). The value of BestTreat lies in the integration of emerging technologies to disentangle the mechanistic details in the complex interactions of microbiota, host metabolism and NAFLD, and provide testable hypotheses for advancing our current understanding of human–microbiota interaction in NAFLD. By using our unique biobank

(made available by SJTU)

, we expect to answer critical questions regarding the manipulation of gut microbiota as a target for NAFLD care therapies

(know-how from UEF and AMC)

. By performing fecal microbiota transplantation (FMT,

pioneered by AMC

) in germ free mice combined with experiments in cell lines and artificial gut systems

(ran by gubra, ChH)

, we aim to discover bacterial strains that protect from or contribute to the onset and progression of NAFLD. By developing unbiased cultivation methods and synthetic biology toolkits

(expertise of DTU and HKI, respectively)

, we aim to improve our ability to genetically modify gut residents for in situ microbiome engineering

(lead by RUG and ChH)

. Lastly, algorithm development for the integration and interrogation of meta-omic data will be exploited for generating probabilistic frameworks for learning persistence and colonization probabilities of microbiome therapeutics

(unique to CLIM and HKI)

. The active participation of end-users in our consortium

(ChH, gubra, Afekta, CLIM)

, as well as technology assessment and communication leaders

(Biofaction, CSBJ, DK4)

, will ensure that the project remains aligned to industry needs and regulatory frameworks for live biotherapeutics.

Follow us